Company Description
Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies.
Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial.
Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds.
It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology.
Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Matthias Alder LIC. IUR., LL.M. |
Contact Details
Address: 4800 Hampden Lane, Suite 200 Bethesda, Maryland 20814 United States | |
| Phone | (301) 500-1556 |
| Website | gaintherapeutics.com |
Stock Details
| Ticker Symbol | GANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001819411 |
| CUSIP Number | 36269B105 |
| ISIN Number | US36269B1052 |
| Employer ID | 85-1726310 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Khalid Islam Ph.D. | Founder and Chairman |
| Matthias Alder LIC. IUR., LL.M. | President, Chief Executive Officer and Director |
| Gene Mack M.B.A. | Chief Financial Officer |
| Dr. Manolo Bellotto Ph.D. | GM and Chief Strategy Officer |
| Dr. Joanne Taylor Ph.D. | Senior Vice President of Research |
| Dr. Terenzio Ignoni Pharm.D. | Senior Vice President of Technical Operations |
| Dr. Jonas Hannestad M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Jan 31, 2024 | 8-K | Current Report |
| Jan 2, 2024 | 424B3 | Prospectus |
| Dec 29, 2023 | EFFECT | Notice of Effectiveness |
| Dec 19, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 24, 2023 | 424B5 | Filing |
| Nov 22, 2023 | 8-K | Current Report |